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Uterine sarcomas are a group of uncommon tumors that account for approximately 1% of malignant
neoplasms of the female genital tract and between 3 and 8.4% of malignant uterine neoplasms.
Objective: To evaluate the factors associated with the clinical behavior of uterine sarcomas.
Materials and methods: In the period from October 1983 to December 2009, clinical ﬁles of patients with
a conﬁrmed diagnosis of uterine sarcoma at the National Institute of Cancerology of Mexico (INCan) were
reviewed and evaluated.
Results: We identiﬁed 77 cases with complete information; average age at presentation was 51.6 years
(range, 14e78 years); most frequent histology was leiomyosarcoma (LMS) in 53/77 (68.8%) cases; most
frequent symptom reported at the time of diagnosis was abnormal vaginal bleeding in 36/77 (46.7%)
cases, and the most frequent clinical stage was clinical stage (CS) I in 31/77 (40.2%) cases. Initial treat-
ment was total abdominal hysterectomy (TAH) and bilateral salpingo-oophrectomy (BSO) in 53/77
(68.9%) cases. Disease-free period was 27.8 months (range, 0e184 months), with disease recurrence in
33/77 (42.85%) cases, most frequent site as lung in 13/33 (39.39%) cases. Management of recurrences was
surgery and chemotherapy (CT) in 5/33 (15.15%) and CT in 10/33 (30.30%) of cases. At present, 40.3% of
the patients (31/77) are found to be Disease-free.
Conclusion: Notwithstanding that uterine sarcomas are aggressive neoplasms, most accepted manage-
ment to date is TAH þ BSO, observing that the fact that this procedure is not performed by oncologists
does not affect the DFP nor OS, contrary to what occurs in other gynecological neoplasms.
 2013 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Uterine sarcomas are a group of infrequent neoplasms that
occupy approximately 1% of malignant gynecologic neoplasms
and represent 3e8.4% of all malignant uterine neoplasms.1,225.
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ciates Ltd. Published by Elsevier LtPreviously, uterine sarcomas were classiﬁed by the World
Health Organization (WHO) as mesenchymal tumors included in
the group of the endometrial sarcoma and smooth muscle tu-
mors.3 The initial classiﬁcation included carcinosarcomas, which
represent 40% of cases, Leiomyosarcomas (LMS) in 40%, Endo-
metrial stromal sarcomas (ESS) in 10e15% of cases, and undiffer-
entiated uterine sarcomas in 10e15% of cases.3 In 2009, the
classiﬁcation of uterine sarcomas changed modifying their staging
and histologic classiﬁcation, consequently their proportional dis-
tribution changed.4e8
Despite that the behavior of these tumors is aggressive; the low
presentation of this entity and its histopathological diversity hasd. All rights reserved.
Table 1
General characteristics of patients.
N ¼ 77 %
Age (years)
Mean 51.6
Range 14e78
Menarche
Mean (years) 13.2
Range (years) 9e18
Family history of cancer 12 (77) 15.5
First grade 12
Second grade 3
FPM
None 58 75.3
IUD 6 7.7
Hormonal 7 9.3
SPC 6 7.7
HRT 0 0
Pregnancies
Mean 4
Range 0e15
Delivery
Mean 3.92
Range 0e13
Cesarean sections
Mean 1.6
Range 0e3
Abortions
Mean 1.88
Range 0e5
AFP (years)
Mean 20.62
Range 15e43
FPM: family planning method; IUD: intrauterine device; SPC: salpingoclasy; HRT:
hormone replacement therapy; AFP: age at ﬁrst pregnancy.
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perform.13
At present, there is scarce evidence on the management of
uterine sarcomas due to their low incidence and histopathological
diversity; furthermore, the recent change in their classiﬁcation has
given rise to the need for conducting new studies to evaluate the
best treatment alternatives in this group of uterine tumors.9e13
In Mexico, to date there are no reports related with this
neoplasm; therefore, it is of the utmost importance to show the
experience acquired in the management of this particular group of
patients in a single reference center.
2. Materials and methods
This is an observational, retrospective study inwhich we reviewed the ﬁles of all
cases diagnosed with uterine sarcomas as well as the pathology reports of the Na-
tional Institute of Cancerology of Mexico (INCan) for the period fromOctober 1983 to
December 2009. The data were obtained through an information search of patients
with a conﬁrmed diagnosis of uterine sarcoma. The study was evaluated and
authorized by the internal review board of the Institute.
2.1. Patients
One hundred and nine patients were identiﬁed at the INCan in a 26-year period;
we excluded 32 cases due to that the new uterine-sarcoma classiﬁcation excludes
those with the diagnosis of carcinosarcomas; consequently 77 cases were suitable
for evaluation.
We assessed the following variables: age; family history of cancer; smoking
habits; age of menarche; parity; age at ﬁrst delivery; related symptoms; clinical
stage; histological type; treatment received; disease-free period (DFP), and time and
site of recurrence, as well as treatment of the latter and overall survival (OS).
2.2. Tumor morphology
The pathology slides of cases reported as uterine sarcomas were retrieved from
the pathology laboratory and re-reviewed by a gynecologic pathologist. Evaluation
of the following variables was performed: histological type; lymphovascular inva-
sion (LVI); myometrial invasion, and spread to other organs. In the case of samples
identiﬁed lymph node tissue, the number of lymph nodes with and without
metastasis was evaluated. Tumor size was assessed in the majority of patients by
measuring the surgical specimen; and cases of not possessing this information due
to the patients’ having been operated on outside of our Institute, the measurements
of the neoplasm were obtained from the pathological report sent by the outside
institution and/or image reports such as ultrasound or CT-scans.
2.3. Treatment
All the informationwas obtained by reviewing the clinical ﬁle, whether through
the report of the surgical procedure performed at our Institute or by the report of the
surgical procedure conducted outside of the Institute; additionally, we reviewed the
cases of patients who did not have surgery as primary treatment.
In cases in which patients received adjuvant treatment with RT, this was re-
ported on the data collection sheet in detail, specifying the technique utilized, tel-
etherapy, brachytherapy, or the combination of both, and the total dose
administered.
Adjuvant management with CT was evaluated in cases of patients who received
this, identifying the type of CT, with one or multiple drugs, and the time of
administration.
2.4. Follow-up
Follow-up data were obtained by reviewing the patients’ clinical ﬁle. The
Disease-free period (DFP) and overall survival (OS) were deﬁned with standard
parameters. In patients lost to follow-up (whether due to a death report in the
majority of cases or to the patient’s withdrawal from follow-up) or those who were
followed-up at other institutions, this information was obtained by telephone
contact.
3. Statistical analysis
We carried out descriptive and inferential statistics including
the Student t test, the Chi square test, or the Fisher exact test ac-
cording to the case. Survival analysis was obtained by means of the
KaplaneMeier test and log-rank comparison. We performed
multivariate analysis with a logistic regression test or Coxmultivariate analysis according to the case for independent factors
in the appearance of recurrence and for evaluation of OS. A value of
p <0.05 was considered statistically signiﬁcant. We used the SPSS
v17 software program for these purposes.
4. Results
4.1. General characteristics of the patients
General demographic characteristics of the 77 evaluated pa-
tients are summarized in Table 1.
4.2. Symptoms
The most frequent symptom was abnormal genital bleeding in
33/77 (46.7%) patients, other symptoms associated are shown in
Table 2.
4.3. Histology, tumor size, and clinical stages
The most frequently identiﬁed histological type was LMS, pre-
senting in 53/77 (68.9%) patients, followed by ESS in 11/77 patients
(14.3%) and another type of uterine sarcoma in 13/77 (16.8%) pa-
tients. Affectation of the lymphovascular space (LVI) was reported
in four cases (5.19%).
Tumor size was determined on all cases by the pathological
study, reporting an average size of 11.9 cm (range, 1e26 cm).
Regarding myometrial invasion, this was absent in 6/77 (7.8%) pa-
tients, with invasion in <50% of the myometrium in 10/77 (12.9%)
patients, invasion of>50% but without affectation of the entire wall
in 7/77 (9.1%) patients, with invasion of the entire wall in 18/77
(23.4%) patients, and in 36/77 cases (46.8%), it was not possible to
Table 2
Clinical characteristics of the study population.
N %
Symptoms
TVB 36 46.7
Pelvic Pain 15 19.4
Pelvic or abdominal mass 24 31.1
Other 2 2.8
Clinical stage
I 31 40.3
II 3 3.9
III 5 6.5
IV 18 23.3
Unknown 20 25.9
Histological type
LMS 53 68.9
ESS 11 14.3
Another type 13 16.8
Histological grade
I 11 14.3
II 3 3.9
III 35 45.4
Unknown 28 36.4
Uterine size (cm)
Average 12.9
Range 7e26
Tumor size (cm)
Average 11.9
Range 1e26
Myometrial invasion
Without invasion 6 7.8
<50% invasion 10 12.9
>50% invasion 7 9.1
Entire wall invasion 18 23.4
Unknown 36 46.8
TVB: transvaginal bleeding; LMS: leiomyosarcoma; ESS: endometrial stromal
sarcoma.
Table 3
Treatment characteristics of the study population.
LMS ESS Other Total %
Surgical procedure (n)
None 7 0 1 8 10.3
TAH þ BSO 36 7 10 53 68.9
Staging 4 0 1 5 6.5
RH 1 1 0 2 2.6
Exenteration 1 2 1 4 5.2
Debulking 4 1 0 5 6.5
Radiotherapy
No 33 8 5 46 59.8
Teletherapy 3 2 2 7 9
Brachytherapy 0 0 0 0 0
Teletherapy and brachytherapy 17 1 6 24 31.2
Chemotherapy
No 30 10 9 49 63.7
Monodrug 3 0 0 3 3.9
Multidrug 20 1 4 25 32.4
Total 53 11 13 77 100
LMS: leiomyosarcoma; ESS: endothelial stromal sarcoma.
TAHD BSO: total abdominal hysterectomy þ bilateral salpingo-oophrectomy; RH:
radical hysterectomy. Staging: as for endometrial carcinoma staging procedure.
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are summarized in Table 2.4.4. Treatment
We recorded the different treatments to which the patients
were initially submitted, it is noteworthy that eight (10.3%) patients
received no treatment, this due to that these patients opted not to
receive any.
Initial treatment in 69/77 (89.6%) patients was surgery. Total
abdominal hysterectomy and bilateral salpingo-oophrectomy
(TAH þ BSO) was performed in 53/77 (68.9%) cases; in ﬁve cases
(6.5%) pelvic lymphadenectomy (LDN) plus additional para-aortic
lymphadenectomy was carried out; in two cases (2.6%), Radical
hysterectomy (RH) was performed; in four cases (5.2%), total pelvic
exenteration was performed, and in ﬁve cases (6.5%), tumor
debulking was conducted, as shown in Table 3.
In cases were LND was performed, none had metastatic disease.Fig. 1. Overall survival.4.5. Adjuvant treatment
Thirty one patients were administered RT as adjuvant treat-
ment, in 28/77 (36.6%) patients, CT was administered, as shown in
Table 3. Schemes had changed during time, thus, we found that
from 1983 to 1995, the most common utilized scheme was dacti-
nomycin/adriamycin, and after that period, the schemes have var-
ied, with the currently most utilized scheme being the combination
of paclitaxel/gemcitabine, while the ifosfamide/adriamycin scheme
is the second most employed. It is noteworthy that one patient
(1.2%) received hormonal therapy after being reported with disease
progression after CT administration; this case was diagnosed as ESSand was managed with anastrazole for 17 months until disease
progression.
On performing a comparison among the different treatments
that have been administered over time in relation to the different
histological strains, it was not possible to ﬁnd a statistically sig-
niﬁcant difference among them (p ¼ 0.376).
4.6. Follow-up
Average follow-up was 35.1 months (range, 1e184 months)
(Fig. 1) and the average Disease-free period (DFP) was 27.8 months
(range, 0e184 months) (Fig. 2).
Recurrent disease presented in 33 cases (42.85%), the most
frequent sites of recurrence presentation were lung in 13/33
(39.39%) patients, retroperitoneum in 4/33 (12.12%), liver in 4/33
(12.12%), and abdominal cavity in 2/33 (6%) patients, and in 7/33
(21.21%) patients disease recurrence presented at other sites.
Treatments administered for recurrence were heterogeneous
different CT schemes were used in 10/33 (30.30%) cases; 5/33
(15.15%) patients were treated with residual disease resection
Fig. 2. Disease free survival.
Fig. 4. Overall survival by histology.
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(45.45%) cases received no treatment because the patients decided
not to attend to the hospital again.
We found 31/77 (40.3%) patients who were alive and without
evidence of disease at follow-up, 8/77 (10.3%) patients who were
alive with disease, and 38/77 (49.3%) patients who had died due to
the disease.
The DFP was similar in relation to the histology of the neoplasm,
as shown in Fig. 3 (log rank, p ¼ 0.789), as OS was similar in the
different histologies, as depicted in Fig. 4 (log rank, p ¼ 0.063).
It is noteworthy to evaluate and mention the group of patients
who had surgery (TAH þ BSO) at other institutions in whom the
presence of a mesenchymal neoplasm at the time of evaluationwas
not suspected. Our interest in this group of patients was to see
whether the recurrence rate was greater in comparison to that ofFig. 3. Disease free survival by histology.patients initially treated at an oncological center. In Fig. 5, DFP is
shown by clinical stage, ﬁnding that there is no statistical difference
among the different groups assigned as early, locally advanced, and
metastatic, or unknown stages, the latter of these having been the
group of patients treated at other institutions (log rank, p ¼ 0.742),
this allocationwas considered because the few cases on every strata
of the FIGO staging. In Fig. 6, a ﬁgure is presented that demonstrates
OS, which found that there is a statistical difference among the
different groups when these are analyzed by clinical stage, withFig. 5. Disease free survival by clinical stage.
Fig. 6. Overall survival by clinical stage.
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p ¼ 0.002).
We carried out Cox multivariate analysis in an attempt to
identify whether there are variables that can exert an inﬂuence on
the Disease-free period (DFP), any of the variables studied prove to
be independent factors.5. Discussion
Uterine sarcomas comprise a rare and heterogeneous group of
neoplasms arising in the mesenchymal cells of the uterus that
exhibit aggressive behavior; their estimated incidence is 1.55 per
100,000 women, and they occupy 1e3% of gynecological tumors
and 3e7% of all uterine tumors.14e16 To date, the data obtained are
derived from studies conducted at other institutions with a small
number of patients; our study is based on the experience of a
referral center during 26 years and includes 77 patients. This study
contributes with relevant information on the result of initial
treatment with or without adjuvant treatment in our milieu,
reﬂecting our experience in the management of these tumors.17,18
In Israel in 2011, a study was reported in which 40 patients with
uterine sarcomas were analyzed, ﬁnding that the most important
prognostic factor for this neoplasm is the clinical stage, which is
similar to our ﬁndings; that is, patients found at the most advancedTable 4
Treatment employed in different series.
Patients (n) Age (years) Surgical procedure (TAH þ BSO
Geller 2004 28 54.4 21
Kapp 2008 1396
Cheng 2011 74 43.5 38
D’Angelo 2011 84 51 68
Naaman 2011 40 53 39
This study 77 51.6 53
TAHD BSO: total abdominal hysterectomy plus bilateral salpingo-oophrectomy; LDN: lym
therapy; DFP: disease free period; NS: not shown.stages correspond to patients who in the end died within a short
time period.18
Standard procedure for staging uterine sarcomas includes Total
abdominal hysterectomy (TAH) with Bilateral salpingo-
oophrectomy (BSO), peritoneal cytology, and biopsy of suspicious
areas of affectation.7 Staging is currently the most important
prognostic factor among all histological types; the most contro-
versial aspect of surgical treatment is the role of optimal cytor-
eduction in advanced disease, the need for performing lymph node
Lymphadenectomy (LDN), and that of preserving the ovaries. In
some studies, the effect of cytoreduction has been evaluated in
patients with disseminated disease; to date, the results are incon-
sistent.19 In our study, we coincide with standard staging man-
agement, because the great majority of our patients were treated
with TAH þ BSO. On the other hand, performing routine LDN is
controversial; at our center, this is not carried out routinely, only 5/
77 (6.49%) cases were submitted to LDN, and no case reported
positive lymph nodes. Thus, lymphadenectomy is not performed
routinely in cases of uterine sarcomas; this is supported by the fact
that no evidence has been found that demonstrates a beneﬁt in
performing the procedure.
The cornerstone of treatment for uterine sarcomas is surgery,
while the use of Radiotherapy to date is controversial, in our study,
we analyzed 31 patients who received RT, of whom 24 received
combined therapy (teletherapy and brachytherapy); the doses
administered ranged between 35 and 50 Gy. However, improve-
ment in OS was not shown in patients who received RT because of
the great heterogeneity, with these results similar to those in re-
ports in the literature.11,20
Management with systemic therapy in uterine sarcomas
currently has fallen in terms of its level of evidence, this is due to
that the carcinosarcoma has been eliminated from the newest
classiﬁcation and has come to be treated as endometrial epithelial
tumor, resulting in the low frequency of uterine sarcomas. There-
fore, we are able to observe that in the past two decades, the
optimal scheme has not been established for treating these tumors.
What has been observed is that schemes that employ adriamycin
prevail over other schemes, whether as monodrug or in combina-
tion, which coincides with our study.21,22
In Table 4, it is possible to observe that the series reported in the
literature do not included large numbers of patients.6,18,23e25 When
our series is compared with those of other authors, we are able to
observe that age at disease presentation is very similar, lympha-
denectomy is not part of the surgical procedure, even though it
continues to be performed in nearly one third of the reported cases;
at our Institute, the procedure is carried out in no more than 5% of
cases diagnosed with this neoplasm.
It is noteworthy that these neoplasms are considered as highly
aggressive and that the follow-up to be applied is broad, reaching
up to several years; in our study, average DFS is 27 months.
On analyzing the cases with regard to DFP, we found no signif-
icant difference on comparing clinical stage and histology; how-
ever, this was not so when analyzing OS because, as expected,) LDN CT RT HRT DFP
13 (46%) 3 14 e 9 months (range, 8e52 months)
348 (25) NS
18 (24) 3 6 25 168 months
12 (14%) 18 13 e 3.5 years (3 monthse8 years)
11 (27%) 10 16 44 months
3 (3.8%) 28 31 1 27.8 months (0e184 months)
phadenectomy; CT: chemotherapy; RT: radiotherapy;HRT: hormonal replacement
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the endometrial stromal sarcoma (ESS), with the worst prognosis
for leiomyosarcomas (LMS).
In conclusion, it is considered that uterine sarcomas are neo-
plasms with aggressive behavior. Diagnosis of these is difﬁcult to
establish prior to surgery due to that there are no studies that
report characteristic ﬁndings. Standard management to date con-
tinues to be Total abdominal hysterectomy plus Bilateral salpingo-
oophorectomy. Lymph node sampling is not carried in routine
fashion. Adjuvant management with chemo- or radiotherapy is not
established routinely because, up to the present, this has not shown
improvement in overall survival, this perhaps due to that in past
decades and to the present day, there has not been a scheme that
shows these beneﬁts, in turn probably due to the low frequency of
uterine sarcomas, due to which it is necessary to conduct more
prospective studies.
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